This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2016 Mar;12(5):577-80.

doi: 10.2217/fon.16.1. Epub 2016 Jan 21.

PARP inhibition in castration-resistant prostate cancer

Lucia Nappi¹, Martin E Gleave¹

Affiliations

PMID: 26792387
DOI: 10.2217/fon.16.1

Editorial

PARP inhibition in castration-resistant prostate cancer

Lucia Nappi et al. Future Oncol. 2016 Mar.

. 2016 Mar;12(5):577-80.

doi: 10.2217/fon.16.1. Epub 2016 Jan 21.

Authors

Lucia Nappi¹, Martin E Gleave¹

Affiliation

¹ Vancouver Prostate Centre & Department of Urologic Science, University of British Columbia, Vancouver, British Columbia, Canada.

PMID: 26792387
DOI: 10.2217/fon.16.1

No abstract available

Keywords: DNA repair gene mutations; PARP inhibitors; castration-resistant prostate cancer; gene sequencing; targeted therapy.

PubMed Disclaimer

Similar articles

A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA, Chen AH, Parikh K. Martin GA, et al. Pharmacotherapy. 2017 Nov;37(11):1406-1414. doi: 10.1002/phar.2027. Pharmacotherapy. 2017. PMID: 28895177 Review.
Olaparib Targets Some Advanced Prostate Cancers.
[No authors listed] [No authors listed] Cancer Discov. 2016 Jan;6(1):OF1. doi: 10.1158/2159-8290.CD-NB2015-161. Epub 2015 Dec 11. Cancer Discov. 2016. PMID: 26658963
Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B, Gui F, Takai T, Feng C, Bai X, Fazli L, Dong X, Liu S, Zhang X, Zhang W, Kibel AS, Jia L. Gui B, et al. Proc Natl Acad Sci U S A. 2019 Jul 16;116(29):14573-14582. doi: 10.1073/pnas.1908547116. Epub 2019 Jul 2. Proc Natl Acad Sci U S A. 2019. PMID: 31266892 Free PMC article.
Stratifying prostate patients for olaparib.
[No authors listed] [No authors listed] Cancer Discov. 2015 Jun;5(6):568-9. doi: 10.1158/2159-8290.CD-NB2015-061. Epub 2015 Apr 22. Cancer Discov. 2015. PMID: 25904654
PARP inhibitors for homologous recombination-deficient prostate cancer.
Christenson ES, Antonarakis ES. Christenson ES, et al. Expert Opin Emerg Drugs. 2018 Jun;23(2):123-133. doi: 10.1080/14728214.2018.1459563. Epub 2018 Apr 4. Expert Opin Emerg Drugs. 2018. PMID: 29595348 Free PMC article. Review.

See all similar articles

Cited by

The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.
Morra F, Merolla F, Napolitano V, Ilardi G, Miro C, Paladino S, Staibano S, Cerrato A, Celetti A. Morra F, et al. Oncotarget. 2017 May 9;8(19):31815-31829. doi: 10.18632/oncotarget.16463. Oncotarget. 2017. PMID: 28415632 Free PMC article.
PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.
Sisay M, Edessa D. Sisay M, et al. Gynecol Oncol Res Pract. 2017 Nov 29;4:18. doi: 10.1186/s40661-017-0055-8. eCollection 2017. Gynecol Oncol Res Pract. 2017. PMID: 29214031 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Other Literature Sources
- scite Smart Citations